Pharma in Focus - knowledge is power

17 - 23 June 2013

Special Report: TGA between a rock and a hard place on CMs
The TGA is regularly criticised for failing to control 'rogue' complementary medicines makers who break promotional regulations but appear to suffer few consequences, but is it hamstrung by a a confused and misdirected regulatory system?

MA downsizing a sad reflection for industry
Medicines Australia CEO, Brendan Shaw, is right when he says that MA's downsizing, announced last week, reflects tough times in industry. It is to be hoped that it is not also a backward step when industry needs to keep as high a profile as possible with government

How to access Pharma in Focus articles

If you're a current subscriber, See below
If you're new to Pharma in Focus, Click here
If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Instant Update: Thurs 20 June
..full report

Govt hikes PBAC application fees
..full report

MA cuts reflect tough times
..full report

GSK's promised cash goes missing
..full report

Women warned off osteo trial
..full report

Legal threat to Pfizer's Lyrica
..full report

Enbrel judged same as generics
..full report

Cancer Council wants patent clarity
..full report

Call for antibiotic access limits
..full report

Latest trials: GSK's drug 'paused'
..full report

Latest ARTG registrations
..full report